Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,399 | 200 | 1,160 |
| Samples | 650 | 118 | 518 |
| Peptides | 579 | 83 | 485 |
Function
WDR7 · WD repeat domain 7
This gene encodes a member of the WD repeat protein family. WD repeats are minimally conserved regions of approximately 40 amino acids typically bracketed by gly-his and trp-asp (GH-WD) that may facilitate formation of heterotrimeric or multiprotein complexes. Members of this family are involved in a variety of cellular processes, including cell cycle progression, signal transduction, apoptosis, and gene regulation. The encoded protein forms the beta subunit of rabconnectin-3 and binds directly with Rab3A GDP/GTP exchange protein and indirectly with Rab3A GDP/GTP activating protein; these proteins are regulators of Rab3 small G protein family members involved in control of the calcium-dependant exocytosis of neurotransmitters. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 569 amino-acid changes on canonical ENST00000254442 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in WDR7 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in WDR7 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 7/40 18% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 3/26 12% | 0/0 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Oral Cavity Carcinoma | 4/54 7% | 0/0 0% |
| Endometrial Carcinoma | 7/42 17% | 32/612 5% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 29/810 4% |
| Non-Small Cell Lung Carcinoma | 18/304 6% | 40/1390 3% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Melanoma | 8/210 4% | 60/1899 3% |
| Colorectal Carcinoma | 18/143 13% | 73/3239 2% |
| Unknown | 0/10 0% | 1/29 3% |
| Gastric Carcinoma | 3/74 4% | 41/1809 2% |
| Other Solid Cancers | 2/94 2% | 30/1515 2% |
| Small Cell Lung Carcinoma | 0/9 0% | 14/752 2% |
| Bladder Carcinoma | 0/58 0% | 18/956 2% |
| Cervical Carcinoma | 0/35 0% | 7/422 2% |
| Non-Cancerous | 1/104 1% | 11/830 1% |
| Neuroendocrine Tumour | 7/154 5% | 2/577 0% |
| Hepatocellular Carcinoma | 2/46 4% | 25/2210 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 28/2550 1% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Esophageal Carcinoma | 0/23 0% | 8/769 1% |
| Other Sarcomas | 2/69 3% | 5/699 1% |
| Burkitts Lymphoma | 0/32 0% | 2/196 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 13/1592 1% |
| Plasma Cell Myeloma | 3/44 7% | 0/305 0% |
| Ovarian Carcinoma | 6/109 6% | 3/998 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Head and Neck Carcinoma | 1/85 1% | 11/1574 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
Mutation Distribution
Where WDR7 is mutated · all tissues, split by cell line vs tissue
How many mutations in WDR7 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,399 mutations in WDR7
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|